Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Chemotherapy in Relapsed or Refractory AML or MDS
NCT00002805Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Aug 1997
- Primary completion
- May 2001
- Modality
- DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
A Phase 2 trial of cladribine, cytarabine, etoposide, mitoxantrone in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Children's Oncology Group. Started Aug 1997; status: completed.
02
Drugs
cladribinecytarabineetoposidemitoxantrone
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00002805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002805.